OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab

OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer With Its
Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)

REDWOOD CITY, Calif., Aug. 22, 2013 (GLOBE NEWSWIRE) -- OncoMed
Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel
therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells,
today announced that the United States Patent and Trademark Office has issued
U.S. Patent No. 8,507,442 to OncoMed for methods of treating cancer with its
antibody vantictumab (OMP-18R5). Vantictumab targets and inhibits the Wnt
pathway, which is believed to be an important CSC pathway. The patent expires
in 2029.

Vantictumab was originally identified at OncoMed from the HuCAL GOLD^®
antibody library (MorphoSys AG) by binding to the Frizzled-7 receptor and was
later determined by OncoMed to bind a novel epitope conserved across five
different Frizzled receptors. Vantictumab has demonstrated broad anti-CSC and
anti-tumor activity in patient-derived xenograft models and is currently being
evaluated in a Phase 1 clinical trial where it has provided early signs of
single-agent activity in patients with neuroendocrine tumors. The antibody is
part of OncoMed's collaboration with Bayer Pharma AG.

OncoMed previously received a U.S. patent claiming the composition of matter
for vantictumab and has corresponding patents or pending patent applications
covering vantictumab in fourteen additional countries and Europe. In addition,
OncoMed has a robust patent portfolio of over 300 patents or pending patent
applications, which includes multiple additional patent families related to
vantictumab or its use.

"OncoMed's new patent, together with its composition-of-matter patent,
provides key patent coverage for vantictumab," said Paul Hastings, Chief
Executive Officer of OncoMed. "The issuance of this patent also further
validates the novelty of this promising antibody and the innovative nature of
OncoMed's ongoing discovery programs, which have not only produced
vantictumab, but also four other anti-CSC agents currently in clinical

About Vantictumab (OMP-18R5)

Vantictumab is a first-in-class antibody that has shown broad anti-CSC and
anti-tumor activity in patient-derived xenograft tumor models. Vantictumab
inhibits a key signaling pathway in cancer, the Wnt pathway. Specifically,
vantictumab selectively targets Frizzled receptors, which are activators of
Wnt signaling. Although vantictumab was originally identified by binding to
Frizzled 7, the antibody selectively targets five different Frizzled
receptors. Vantictumab is currently being evaluated in a Phase 1 clinical
trial. Vantictumab is part of OncoMed's collaboration with Bayer Pharma AG.

About Cancer Stem Cells

Cancer stem cells, or CSCs, are the subpopulation of cells in a tumor
responsible for driving growth and metastasis of the tumor. CSCs, also known
as tumor-initiating cells, exhibit certain properties which include the
capacity to divide and give rise to new CSCs via a process called self-renewal
and the capacity to differentiate or change into the other cells that form the
bulk of the tumor. Common cancer drugs target bulk tumor cells but have
limited impact on CSCs, thereby providing a path for recurrence of the tumor.
OncoMed's product candidates target CSCs by blocking self-renewal and driving
differentiation of CSCs toward a non-tumorigenic state, and also impact bulk
tumor cells. OncoMed believes its product candidates are distinct from the
current generations of chemotherapies and targeted therapies, and have the
potential to significantly impact cancer treatment and the clinical outcome of
patients with cancer.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and
developing novel therapeutics targeting cancer stem cells. OncoMed has five
anti-cancer product candidates in clinical development, including demcizumab
(Anti-DLL4, OMP-21M18), OMP-59R5 (Anti-Notch2/3), OMP-52M51 (Anti-Notch1),
vantictumab (Anti-Fzd7, OMP-18R5), and OMP-54F28 (Fzd8-Fc), which target key
cancer stem cell signaling pathways including Notch and Wnt. OncoMed has two
other antibodies in preclinical development with Investigational New Drug
filings planned for as early as 2014. OncoMed is also pursuing discovery of
additional novel anti-CSC product candidates.OncoMed has formed strategic
alliances with Bayer Pharma AG and GlaxoSmithKline (GSK). Additional
information can be found at the company's website: www.oncomed.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not
descriptions of historical facts regarding OncoMed Pharmaceuticals, they are
forward-looking statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, including OncoMed's expectations
regarding the scope, validity, enforceability and duration of patent
protection afforded by the referenced patents and OncoMed's other intellectual
property; OncoMed's ability to successfully enforce its intellectual property
and defend it against challenges by third parties; OncoMed's ability to obtain
additional patent protection for vantictumab and its other product candidates
in the U.S. and additional countries; the success of clinical trials for
vantictumab and the potential of vantictumab to improve patient outcomes,
particularly in neuroendocrine patients; the potential of OncoMed's product
candidates to significantly impact CSCs, cancer treatment and the clinical
outcome of patients with cancer; the success of OncoMed's discovery efforts in
producing novel therapeutic agents; and the timing of Investigational New Drug
filings. Such forward-looking statements involve substantial risks and
uncertainties that could cause OncoMed's clinical development programs, future
results, performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in the
preclinical and clinical development process; the risks and uncertainties of
the regulatory approval process; OncoMed's dependence on its collaboration
partners, including GSK and Bayer, for the funding of its partnered programs;
OncoMed's ability to raise additional capital to support the development of
its unpartnered programs; OncoMed's dependence on the development and
marketing efforts of its partners for the commercial success of its partnered
product candidates; OncoMed's reliance on third parties to conduct certain
preclinical studies and all of its clinical trials; OncoMed's reliance on
single source third-party contract manufacturing organizations to manufacture
and supply its product candidates; OncoMed's ability to validate, develop and
obtain regulatory approval for companion diagnostics; OncoMed's ability to
achieve market acceptance and commercial success of its product candidates
once regulatory approval is achieved; OncoMed's ability to discover, develop
and commercialize additional product candidates; the ability of competitors to
discover, develop or commercialize competing products more quickly or more
successfully; OncoMed's dependence on its President and Chief Executive
Officer, its Chief Scientific Officer, its Chief Medical Officer and other key
executives; risk of third party claims alleging infringement of patents and
proprietary rights or seeking to invalidate OncoMed's patents or proprietary
rights; and the ability of OncoMed's proprietary rights to protect its
technologies and product candidates. OncoMed undertakes no obligation to
update or revise any forward-looking statements. For a further description of
the risks and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as risks relating
to OncoMed's business in general, see OncoMed's Prospectus filed with the
Securities and Exchange Commission on July 18, 2013.

CONTACT: Investor Contact:
         OncoMed Pharmaceuticals
         Shari Annes
         Investor Relations
         (650) 888-0902
         Media Inquiries:
         BCC Partners
         Karen L. Bergman or
         Michelle Corral
         (650) 575-1509 or (415) 794-8662
         kbergman@bccpartners.com or

OncoMed Pharmaceuticals, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.